fashion -WSS

fashion

author：leisure time 2025-09-11 10:28:54 - browse：7

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market.

The treatment, Lumakras, is designed to treat lung cancer caused by a specific genetic mutation to a protein called KRAS. It’s one of the most common genetic mutations in cancer, but repeated clinical trial failures had led researchers to deem it “undruggable” until a glimmer of hope came about a decade ago.

Lumakras received an accelerated, or conditional, approval in May 2021, making it the first KRAS drug on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

WSS

Stem cell treatment guidelines are released by FDA

How to fix cancer clinical trials' diversity problem

ALS advocates say criticism of new drugs misses bigger picture

House transparency, PBM reform bill gains bipartisan support

How generative AI is inspiring dreams of a health data revolution

Elizabeth Holmes banned from government health programs

focus

fashion

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

A new House health package & hospitals’ new site

Duchenne breakthrough therapy leaves behind pioneering families

Medicaid rebukes states for mistakenly disenrolling children

State Dept. review finds Biden bears some blame for Afghanistan failures

Why doctors need education on FDA device approval process

ChatGPT in medicine: STAT answers readers' burning questions

FDA clears AI tool for detecting skin cancer

How to save PrEP access — and even expand it

AstraZeneca chief proposes a novel edit to the drug pricing bill

entertainment

EU regulator recommends expanding Mounjaro approval to obesity

Humana sues Biden admin over Medicare Advantage audit rule

Snackable artificial intelligence, expert AI, and the pharma industry

FDA clears AI tool for detecting skin cancer

A new House health package & hospitals’ new site

eGenesis tests gene

hotspot

focus

focus

explore